CoChat
Sign Up
Cited by 204

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Strategies for targeted drug delivery in treatment of colon cancer: current trends and future perspectives

Banerjee, Antara, Pathak, Surajit, Subramanium, Vimala Devi, G., Dharanivasan, Murugesan, Ramachandran, Verma, Rama S.·2017·Drug Discovery Today
DOI 10.1016/j.drudis.2017.05.006
Open this paper in CoChat — free account

Abstract

Despite advances in treatment modalities, colon cancer (CC) is the third most common cause of cancer-related death worldwide. Subsequent unfavorable effects owing to toxicity of conventional drugs are a challenging problem associated with chemotherapy. There is noticeable concern toward site-specific/targeted delivery of chemotherapeutic drugs specifically to the affected site of the colon in a predictable and reproducible manner. However, the biggest challenge in successful drug targeting for the colon is avoidance of drug absorption and/or degradation in the upper gastrointestinal tract before the drug reaches the colon. Nanoparticles endowed with targeting abilities offer a novel approach for site-specific delivery of chemotherapeutic agents. The present review focuses on recent approaches for colon-specific drug delivery (CDDS) and aims to unveil the emerging possibilities and advances in the treatment of CC with CDDS.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2017.05.006

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 4 references

Research works printed but not linked: 76

  1. Ilyas, 1999, Genetic pathways in colorectal and other cancers, Eur. J. Cancer, 35, 335, 10.1016/S0959-8049(98)00431-6 · DOI
  2. Jemal, 2010, Cancer statistics, Cancer J. Clin., 60, 277, 10.3322/caac.20073 · DOI · Paper page
  3. Tang, 2015, Co-delivery of docetaxel and poloxamer 235 by PLGA-TPGS nanoparticles for breast cancer treatment, Mater. Sci. Eng. C Mater. Biol. Appl., 49348
  4. Ades, 2009, Adjuvant chemotherapy for colon cancer in the elderly: moving from evidence to practice, Oncology, 23162
  5. Son, 2009, Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy, Yonsei Med. J., 50, 796, 10.3349/ymj.2009.50.6.796 · DOI
  6. Wang, 2009, Nanoparticle delivery of cancer drugs, Annu. Rev. Med., 63, 185, 10.1146/annurev-med-040210-162544 · DOI
  7. Brigger, 2012, Nanoparticles in cancer therapy and diagnosis, Adv. Drug Deliv. Rev., 6424
  8. Mohanraj, 2006, Nanoparticles—a review, Trop. J. Pharm. Res., 5, 561
  9. Chen, 1994, Synthesis of albumin-dextran sulfate microspheres possessing favourable loading and release characteristics for the anti-cancer drug doxorubicin, J. Control Rel., 31, 49, 10.1016/0168-3659(94)90250-X · DOI
  10. Menter, 2014, Convergence of nanotechnology and cancer prevention: are we there yet?, Cancer Prev. Res., 7, 973, 10.1158/1940-6207.CAPR-14-0079 · DOI
  11. Chabot, 1997, Clinical pharmacokinetics of irinotecan, Clin. Pharmacokinet., 33, 245, 10.2165/00003088-199733040-00001 · DOI
  12. Xie, 2016, EpCAM aptamer-functionalized mesoporous silica nanoparticles for efficient colon cancer cell-targeted drug delivery, Eur. J. Pharm. Sci., 83, 28, 10.1016/j.ejps.2015.12.014 · DOI
  13. Lea, 2010, BRAF p. Val600Glu (V600E) testing for assessment of treatment options in metastatic colon cancer, PLoS Curr., 2, RRN1187, 10.1371/currents.RRN1187 · DOI
  14. Heinemann, 2003, Targeted therapy in metastatic colon cancer – an example of personalised medicine in action, Cancer Treat. Rev., 39, 592, 10.1016/j.ctrv.2012.12.011 · DOI
  15. Chee, 2010, Targeted therapeutic agents for colon cancer, Gastroenterol. Clin. N. Am., 39, 601, 10.1016/j.gtc.2010.08.017 · DOI
  16. Song, 2013, Folic acid-chitosan conjugated nanoparticles for improving tumor-targeted drug delivery, BioMed Res. Int., 723158
  17. Humphries, 2000, Integrin structure, Biochem. Soc. Trans., 28, 311, 10.1042/bst0280311 · DOI
  18. Hynes, 2002, Integrins: bidirectional, allosteric signaling machines, Cell, 110, 673, 10.1016/S0092-8674(02)00971-6 · DOI
  19. Johnson, 2009, Integrins during evolution: evolutionary trees and model organisms, Biochim. Biophys. Acta, 1788, 779, 10.1016/j.bbamem.2008.12.013 · DOI
  20. Khan, 2011, Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo, PLoS One, 6, 20347, 10.1371/journal.pone.0020347 · DOI
  21. Reddy, 2003, Integrin receptors: the dynamic modulators of endometrial function, Tissue Cell, 35, 260, 10.1016/S0040-8166(03)00039-9 · DOI
  22. LaRocque, 2009, Cancer detection and treatment: the role of nanomedicines, Mol. Biotechnol., 42, 358, 10.1007/s12033-009-9161-0 · DOI
  23. Muller, 2016, Molecular pathological classification of colon cancer, Virchows Arch., 469, 125, 10.1007/s00428-016-1956-3 · DOI
  24. Ren, 2015, A new peptide ligand for colon cancer targeted delivery of micelles, Drug Deliv., 23, 1763, 10.3109/10717544.2015.1077293 · DOI · Paper page
  25. Cabner, 2005, Timeline: chemotherapy and the war on cancer, Nat. Rev. Cancer, 5, 65, 10.1038/nrc1529 · DOI
  26. Das, 2011, Epithelial cell adhesion molecule targeted Nutlin-3a loaded immunonanoparticles for cancer therapy, ActaBiomater, 7, 355
  27. Sonnemann, 2011, Anticancer effects of the p53 activator Nutlin-3 in Ewing’s sarcoma cells, Eur. J. Cancer, 47, 1432, 10.1016/j.ejca.2011.01.015 · DOI
  28. Fonseca, 2002, Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity, J. Control. Release, 83, 273, 10.1016/S0168-3659(02)00212-2 · DOI
  29. Song, 2009, Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles, Eur. J. Pharm. Sci., 37, 300, 10.1016/j.ejps.2009.02.018 · DOI
  30. Ming, 2015, Enhanced efficacy of chemotherapeutic drugs against colon cancer using ligand-decorated self-breakable agents, RSC Adv., 5, 92361, 10.1039/C5RA16175D · DOI
  31. Gokce, 2012, A comparative evaluation of coenzyme Q10-loaded liposomes and solid lipid nanoparticles as dermal antioxidant carriers, Int. J. Nanomed., 7, 5109
  32. De Gramont, 2011, Re-challenge and the concept of lines of therapy in metastatic colon cancer, Eur. J. Cancer, 47, 76, 10.1016/S0959-8049(11)70150-2 · DOI
  33. Vats, 2012, Tabletted guar gum microspheres of piroxicam for targeted adjuvant therapy for colonic adenocarcinomas, Ther. Deliv., 3, 1281, 10.4155/tde.12.116 · DOI
  34. Ashwanikumar, 2012, Methacrylic-based nanogels for the pH-sensitive delivery of 5-fluorouracil in the colon, Int. J. Nanomed., 7, 5769
  35. Dhawale, 2010, Formulation and evaluation porous microspheres of 5-fluorouracil for colon targeting, Int. J. Pharm. Tech. Res., 2, 1112
  36. Smitha, 2013, In vitro evaluation of paclitaxel loaded amorphous chitin nanoparticles for colon cancer drug delivery, Colloids Surf. B Biointerfaces, 104, 245, 10.1016/j.colsurfb.2012.11.031 · DOI
  37. Katarzyna, 2015, Magnetic nanoparticles enhance the anticancer activity of cathelicidin LL-37 peptide against colon cancer cells, Int. J. Nanomed., 10, 3843
  38. Loira, 2014, Delivery strategies for sustained drug release in the lungs, Adv. Drug Deliv. Rev., 75, 81, 10.1016/j.addr.2014.05.017 · DOI
  39. Patel, 2008, Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colon cancer, Pharmacotherapy, 28, 31, 10.1592/phco.28.11-supp.31S · DOI
  40. Yang, 2011, Oxaliplatin long circulating liposomes improved therapeutic index of colorectal carcinoma, BMC Biotechnol., 11, 21, 10.1186/1472-6750-11-21 · DOI
  41. Cay, 1997, Liver metastases from colon cancer: drug delivery with liposome-encapsulated doxorubicin, Radiology, 205, 95, 10.1148/radiology.205.1.9314969 · DOI
  42. Ashish, 2010, Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide, Int. J. Pharm., 366, 201
  43. Koning, 2002, Efficient intracellular delivery of 5-fluorodeoxyuridine into colon cancer cells by targeted immunoliposomes, Cancer Detect. Prev., 26, 299, 10.1016/S0361-090X(02)00087-9 · DOI
  44. Jalalian, 2013, Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo, Eur. J. Pharm. Sci., 50, 191, 10.1016/j.ejps.2013.06.015 · DOI
  45. Esmaelbeygi, 2015, Role of iron oxide core of polymeric nanoparticles in the thermosensitivity of colon cancer cell line HT-29, Int. J. Hyperth., 31, 489, 10.3109/02656736.2015.1035766 · DOI
  46. Mannucci, 2014, Magnetic nanoparticles from Magnetospirillum gryphiswaldense increase the efficacy of thermotherapy in a model of colon carcinoma, PLoS One, 9, e108959, 10.1371/journal.pone.0108959 · DOI
  47. Kulamarva, 2008, In vitro cytotoxicity of functionalized single walled carbon nanotubes for targeted gene delivery applications, Nanotoxicology, 2, 184, 10.1080/17435390802464994 · DOI
  48. Lee, 2013, Targeting colon cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibody, Biomaterials, 34, 8756, 10.1016/j.biomaterials.2013.07.067 · DOI
  49. Sadrolhosseini, 2014, Application of polypyrrole multi-walled carbon nanotube composite layer for detection of mercury, lead and iron ions using surface plasmon resonance technique, PLoS One, 9, e93962, 10.1371/journal.pone.0093962 · DOI
  50. Wen, 2013, Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes, Adv. Healthc. Mater., 2, 1267, 10.1002/adhm.201200389 · DOI
  51. Wu, 2013, PEGylated multi-walled carbon nanotubes for encapsulation and sustained release of oxaliplatin, Pharm. Res., 30, 2412, 10.1007/s11095-012-0883-5 · DOI
  52. Derusha, 2014, Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors, Int. J. Nanomed., 9, 589
  53. Ortiz, 2015, Poly(butylcyanoacrylate)andpoly(epsilon-caprolactone) nanoparticlesloadedwith5-fluorouracilincrease the cytotoxic effect of the drug in experimental colon cancer, AAPS J., 17, 918, 10.1208/s12248-015-9761-5 · DOI
  54. Xiao, 2015, Hyaluronic acid-functionalized polymeric nanoparticles for colon cancer-targeted combination chemotherapy, Nanoscale, 7, 217745, 10.1039/C5NR04831A · DOI · Paper page
  55. Malhotra, 2013, Systemic siRNA delivery via peptide-tagged polymeric nanoparticles, targeting PLK1 gene in a mouse xenograft model of colon cancer, Int. J. Biomater., 2013, 252531, 10.1155/2013/252531 · DOI
  56. Li, 2014, Epithelial cell adhesion molecule aptamer functionalized PLGA-lecithin-curcumin-PEG nanoparticles for targeted drug delivery to human colorectal adenocarcinoma cells, Int. J. Nanomed., 21, 1083
  57. Konda, 2002, Biodistribution of a 153 gd-folate dendrimer, generation=4, in mice with folate-receptor positive and negative ovarian tumor xenografts, Invest. Radiol., 37, 199, 10.1097/00004424-200204000-00005 · DOI
  58. Wang, 2003, Mechanism of enhancement effect of dendrimer on transdermal drug permeation through polyhydroxyalkanoate matrix, J. Biosci. Bioeng., 96, 537, 10.1016/S1389-1723(04)70146-2 · DOI
  59. Gillies, 2002, Designing macromolecules for therapeutic applications: polyester dendrimer-poly (ethylene oxide) “bow-tie” hybrids with tunable molecular weight and architecture, J. Am. Chem. Soc., 124, 14137, 10.1021/ja028100n · DOI
  60. Kolhe, 2003, Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers, Int. J. Pharm., 259, 143, 10.1016/S0378-5173(03)00225-4 · DOI
  61. Baker, 2013, Why I believe nanoparticles are crucial as a carrier for targeted drug delivery, Rev. Nanomed. Nanobiotechnol., 5, 423, 10.1002/wnan.1226 · DOI
  62. James, 2009, Dendrimer-based nanoparticles for cancer therapy, ASH Hematol., 2009, 708, 10.1182/asheducation-2009.1.708 · DOI
  63. Quintana, 2002, Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor, Pharm. Res., 19, 1310, 10.1023/A:1020398624602 · DOI
  64. Luo, 2002, Poly (ethylene glycol)-conjugated PAMAM dendrimer for biocompatible, high-efficiency DNA delivery, Macromolecules, 35, 3456, 10.1021/ma0106346 · DOI
  65. Patri, 2004, Synthesis and in vitro testing of j591 antibody-dendrimer conjugates for targeted prostate cancer therapy, Bioconjug. Chem., 15, 1174, 10.1021/bc0499127 · DOI
  66. Thomas, 2005, Targeting and inhibition of cell growth by an engineered dendritic nanodevice, J. Med. Chem., 48, 3729, 10.1021/jm040187v · DOI
  67. Shukla, 2006, Her2 specific tumor targeting with dendrimer conjugated anti-her2 mab, Bioconjug. Chem., 17, 1109, 10.1021/bc050348p · DOI
  68. Jingjing, 2015, Multivalent conjugation of antibody to dendrimers for the enhanced capture and regulation on colon cancer cells, Sci. Rep., 5, 9445, 10.1038/srep09445 · DOI
  69. Huang, 2015, Fine-tuning vitamin E-containing telodendrimers for efficient delivery of gambogic acid in colon cancer treatment, Mol. Pharm., 12, 1216, 10.1021/acs.molpharmaceut.5b00051 · DOI
  70. Chen, 2011, Silicon nanowire field-effect transistor-based biosensors for biomedical diagnosis and cellular recording investigation, Nano Today, 6, 131, 10.1016/j.nantod.2011.02.001 · DOI
  71. Tivony, 2014, Biomedical imaging of colon cancer by near infrared fluorescent nanoparticles, J. Biomed. Nanotechnol., 10, 1041, 10.1166/jbn.2014.1799 · DOI
  72. Huang, 2013, Anti-CEA-functionalized superparamagnetic iron oxide nanoparticles for examining colorectal tumors in vivo, Nanoscale Res. Lett., 8, 413, 10.1186/1556-276X-8-413 · DOI
  73. Mehravi, 2013, Cellular uptake and imaging studies of glycosylated silica nanoprobe (GSN) in human colon adenocarcinoma (HT 29 cell line), Int. J. Nanomed., 8, 3209, 10.2147/IJN.S44815 · DOI
  74. Byoung, 2012, Polymeric photosensitizer nano drug for long term therapeutic effect; in vitro and in vivo phototoxicity against human colon cancer (HCT116), J. Photopolyme Sci. Technol., 25, 713, 10.2494/photopolymer.25.713 · DOI
  75. Creixel, 2010, Preparation of epidermal growth factor (EGF) conjugated iron oxide nanoparticles and their internalization into colon cancer cells, J. Magn. Magn. Mater., 322, 62425
  76. Juliette, 2012, Fluorescent nanoprobes dedicated to in vivo imaging: from preclinical validations to clinical translation, Molecules, 17, 5564, 10.3390/molecules17055564 · DOI

Cited by

Sorted by citations

Metadata

Authors
Banerjee, A., Pathak, S., Subramanium, V. D., G., D., Murugesan, R., & Verma, R. S.
ORCID
Verma, Rama S.
Venue
Drug Discovery Today
Publisher
Elsevier BV
Published
2017-08
Volume
22
Issue
8
Pages
1224-1232
ISSN
1359-6446
DOI
10.1016/j.drudis.2017.05.006
Cited by
204
References
4
Language
en
Licence
Funders
Chettinad Academy of Research and Education, Chennai and IIT-Madras, India

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review